| Name | Title | Contact Details |
|---|
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.
Since 1983, Schulman has provided the research community with IRB review services of the highest quality. In establishing the IRB, our founders sought to promote clinical research by helping to safeguard the rights and welfare of clinical research subjects. Schulman’s team of dedicated professionals seeks to provide timely, quality services based on the foundation of respect for persons, beneficence and justice. Through continuous quality improvement and rigorous training on human subject protection, Schulman provides thorough, ethical, responsive and thoughtful review of research studies. By combining impeccable review standards, savvy industry insight, responsive customer service and innovative technological solutions, Schulman creates a review experience that goes beyond the expected. We look forward to continued collaboration with our colleagues in North America and around the world as we uphold our mission to protect the rights and welfare of clinical research subjects.
Stonegate Community Health Centre is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
S Epilepsy is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advanced Coding Solutions is a White House, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.